Xilio Therapeutics (XLO) Return on Capital Employed (2021 - 2026)
Xilio Therapeutics (XLO) reported Return on Capital Employed of 36.38% for Q1 2026, up 10685.0% on a YoY basis from N/an in Q1 2025, and up 23.82% sequentially from 47.75% in Q4 2025.
Xilio Therapeutics (XLO) Return on Capital Employed (2021 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 6 years of Return on Capital Employed data on file, last reported at 36.38% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 10685.0% year-over-year to 36.38%; the trailing twelve-month figure through Mar 2026 stood at 36.38% (up 10685.0% YoY), and the FY2025 full-year result was 74.16%, up 8222.0% from the prior year.
- Return on Capital Employed advanced to 36.38% in Q1 2026, from 47.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 36.38% in Q1 2026 to a low of 181.89% in Q1 2024.
- A 5-year average of 96.88% and a median of 86.42% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 9810 bps in 2024 and surged 10685 bps in 2026, its largest moves.
- Tracing XLO's Return on Capital Employed over 5 years: stood at 70.1% in 2022, then slumped by 111 bps to 148.11% in 2023, then advanced by 10 bps to 132.84% in 2024, then surged by 64 bps to 47.75% in 2025, then climbed by 24 bps to 36.38% in 2026.
- Business Quant data shows XLO's Return on Capital Employed at 36.38% in Q1 2026, 47.75% in Q4 2025, and 56.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -36.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.38% |
| Dec 31, 2025 | -47.75% |
| Sep 30, 2025 | -56.59% |
| Jun 30, 2025 | -86.42% |
| Mar 31, 2025 | -143.23% |
| Dec 31, 2024 | -132.84% |
| Sep 30, 2024 | -147.10% |
| Jun 30, 2024 | -142.19% |
| Mar 31, 2024 | -181.89% |
| Dec 31, 2023 | -148.11% |
| Sep 30, 2023 | -123.47% |
| Jun 30, 2023 | -101.61% |
| Mar 31, 2023 | -83.79% |
| Dec 31, 2022 | -70.10% |
| Sep 30, 2022 | -56.67% |
| Jun 30, 2022 | -47.97% |
| Mar 31, 2022 | -40.90% |
| Dec 31, 2021 | -47.92% |